Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.

Bryan D FlemingDaniel J UrbanMatthew D HallThomas LongerichTim F GretenIra PastanMitchell Ho

Published in: Hepatology (Baltimore, Md.) (2020)

These data indicate that ABD-containing deimmunized HN3-T20 immunotoxins are high-potency therapeutics ready to be evaluated in clinical trials for the treatment of liver cancer.

Keyphrases

clinical trial
electronic health record
small molecule
big data
combination therapy
machine learning
open label
replacement therapy
study protocol
phase iii